

Watanabe T, Asano N, Meng G, Yamashita K, Arai Y, Sakurai T, <u>Kudo M</u> , Fuss IJ, Kitani A, Shimosegawa T, Chiba T, Strober W	NOD2 Down-regulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6.	Mucosal Immunol			2014 (in press)
<u>Kudo M</u>	Prediction of incidence risk of hepatocellular carcinoma by ultrasound elastography.	Liver Cancer			2014 (in press)
Kawanaka M, Nishio K, Nakamura J, Oka T, Urata N, Goto D, Suehiro M, Kawamoto H, <u>Kudo M</u> , Yamada G	Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy.	Liver Cancer			2014 (in press)
Nishida N, <u>Kudo M</u>	Alteration of epigenetic profile in human hepatocellular carcinoma and its clinical implications.	Liver Cancer			2014 (in press)
Minami Y, Yagyu Y, Murakami T, <u>Kudo M</u>	Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma using Three-Dimensional Cone-Beam CT Angiography.	Liver Cancer			2014 (in press)
<u>Kudo M</u>	Advances in Liver Fibrosis Imaging and Hepatocellular Carcinoma: Update in 2013.	Oncology	84	1-2	2013
Fujimoto K, Kato M, <u>Kudo M</u> , Yada N, Shiina T, Ueshima K, Yamada Y, Ishida T, Azuma M, Ymasaki M, Yamamoto K, Hayashi N, Takehara T	Novel image analysis method using ultrasound elastography for non-invasive evaluation of hepatic fibrosis in patients with chronic hepatitis C.	Oncology	84	3-12	2013
Yada N, Morikawa H, Fujimoto K, Kato M, Kawada N, <u>Kudo M</u>	Assessment of liver fibrosis with real-time tissue elastography in chronic viral hepatitis.	Oncology	84	13-20	2013
<u>Kudo M</u> , Matsui O, Sakamoto M, Kitao A, Kim T, Ariizumi S, Ichikawa T, Kobayashi S, Imai Y, Izumi N, Fujinaga Y, Ariei S	Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA MRI) in the management of hepatocellular carcinoma: Consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan.	Oncology	84	21-27	2013

Inoue T, <u>Kudo M</u> , Hatanaka K, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Minami Y, Sakurai T, Ueshima k, Nishida N	Usefulness of contrast-enhanced ultrasonography to evaluate the post treatment responses of radiofrequency ablation for hepatocellular carcinoma; comparison with dynamic CT.	Oncology	84	51-57	2013
Minami Y, <u>Kudo M</u>	Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: US, CT and MRI.	Oncology	84	58-63	2013
Minata M, Harada K, <u>Kudo M</u> , Ikai I, Nishida N	The prognostic value of vascular endothelial growth factor in hepatocellular carcinoma for predicting metastasis after curative resection.	Oncology	84	75-81	2013
Nishida N, Arizumi T, Takita M, Nagai T, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Ida H, <u>Kudo M</u>	Quantification of tumor DNA in serum and vascular invasion of human hepatocellular carcinoma.	Oncology	84	82-87	2013
Minata M, <u>Kudo M</u> , Harada K, Ikai I, Nishida N	Expression of E-cadherin and vascular endothelial growth factor in non-cancerous liver is associated with recurrence of HCC after curative resection.	Oncology	84	88-92	2013
Nishida N, <u>Kudo M</u>	Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma.	Oncology	84	93-97	2013
Claudon M, Dietrich CF, Choi BI, Cosgrove DO, <u>Kudo M</u> , Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX	Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.	Ultrasound Med Biol	39	187-210	2013

Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, <u>Kudo M</u> , Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, for the Liver Cancer Study Group of Japan.	Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey.	J Hepatol	58	724-729	2013
Sakurai T, <u>Kudo M</u> , Umemura A, He G, Elsharkawy AM, Seki E, Karin M	p38 $\alpha$ inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species.	Cancer Res	73	215-224	2013
Claudon M, Dietrich CF, Choi BI, Cosgrove DO, <u>Kudo M</u> , Nolsoe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX	Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.	Ultraschall Med	34	11-29	2013
Watanabe T, Yamashita K, Sakurai T, <u>Kudo M</u> , Shiokawa M, Uza N, Kadoma Y, Uchida K, Okazaki K, Chiba T	Toll-like receptor activation in basophils contributes to the development of IgG4-related disease.	J Gastroenterol	48	247-253	2013
Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, <u>Kudo M</u> , Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Ceng AL	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).	Liver Int	33	327-337	2013
Minami Y, <u>Kudo M</u>	Radiofrequency ablation of liver metastases from colorectal cancer: a literature review.	Gut Liver	7	1-6	2013
Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa K, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Hidenori Toyoda, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Ariei S, Nishio K, <u>Kudo M</u>	FGF3/FGF4 Amplification and Multiple lung Metastases in responders to sorafenib in hepatocellular carcinoma.	Hepatology	57	1407-1415	2013

Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi K, Katsushima S, <u>Kudo M</u> , Takaguchi K, Hiasa Y, Chayama K, Yatsushashi H, Oketani M, Kumada H	Inhibition of hepatocellular carcinoma by PegIFN $\alpha$ -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.	J Gastroenterol	48	382-390	2013
Takayasu K, Arii S, Sakamoto M, Matsuyama Y, <u>Kudo M</u> , Ichida T, Nakashima O, Matsui O, Izumi N, Ku Y, Kokudo N, Makuuchi M, Liver Cancer Study Group of Japan	Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm.	Liver Int	33	762-770	2013
Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, Kogita S, Kumano S, <u>Kudo M</u> , Mochizuki T	Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma.	Radiology	266	480-490	2013
Hagiwara S, <u>Kudo M</u> , Osaki Y, Matsuo H, Inuzuka T, Matsumoto A, Tanaka E, Sakurai T, Ueshima K, Inoue T, Yada Y, Nishida N	Impact of peginterferon Alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.	J Med Virol	85	987-95	2013
<u>Kudo M</u>	Early Hepatocellular Carcinoma: Definition and Diagnosis.	Liver Cancer	2(2)	69-72	2013
Inaba Y, Kanai F, Aramaki T, Yamamoto T, Tanaka T, Yamakado K, Kaneko S, <u>Kudo M</u> , Imanaka K, Kora S, Nishida N, Kawai N, Seki H, Matsui O, Arioka H, Arai Y	A randomized phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolization.	Eur J Cancer	49	2832-2840	2013
<u>Kudo M</u>	Chronic liver diseases and hepatocellular carcinoma: update in 2013.	Digest Dis	31	405-407	2013
Nishida N, Iwamura S, Ida H, Hagiwara S, Kagioka Y, Minami Y, Maetani Y, Itoh K, <u>Kudo M</u>	Clinical and histological features of different types of Budd-Chiari syndrome: A Comparison of 4 cases.	Digest Dis	31	408-414	2013
Yada N, <u>Kudo M</u> , Chung H, Watanabe T	Autoimmune hepatitis and immunoglobulin G4-associated autoimmune Hepatitis.	Digest Dis	31	415-420	2013

Sugimoto K, Kim SR, Shamy AE, Imoto S, Ando K, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Takashi H, Hotta H, Hayashi Y, <u>Kudo M</u>	Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance.	Digest Dis	31	421-425	2013
Kim SR, Shamy AE, Imoto S, Kim KI, Sugimoto K, Kim SK, Tanaka Y, Hatae T, Hasegawa Y, Fujinami A, Ohta M, Hotta H, <u>Kudo M</u>	Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load.	Digest Dis	31	426-433	2013
Sugimoto K, Kim SR, Shamy AE, Imoto S, Fujioka H, Kim KI, Tanaka Y, Yano Y, Kim SK, Hasegawa Y, Fujinami A, Ohta M, Hatae T, Hotta H, Hayashi Y, <u>Kudo M</u>	Outcome of double-filtration plasmapheresis plus IFN treatment in non-responders to pegylated IFN plus ribavirin combination therapy.	Digest Dis	31	434-439	2013
Sakurai T, <u>Kudo M</u> , Watanabe T, Itoh K, Higashitsuji H, Arizumi T, Inoue T, Hagiwara S, Ueshima K, Nishida N, Fukumoto M, Fujita J	Hypothermia Protects against Fulminant Hepatitis in Mice by Reducing Reactive Oxygen Species Production.	Digest Dis	31	440-446	2013
Nishida N, <u>Kudo M</u>	Oxidative stress and epigenetic instability in human hepatocarcinogenesis.	Digest Dis	31	447-453	2013
Kim SK, Marusawa H, Eso Y, Chiba T, <u>Kudo M</u>	Novel mouse models of hepatocarcinogenesis with stepwise accumulation of genetic alterations.	Digest Dis	31	454-458	2013
Nishida N, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, <u>Kudo M</u>	Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesis.	Digest Dis	31	459-466	2013
Tsuji N, Ishiguro S, Sasaki Y, <u>Kudo M</u>	CD-34 expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma.	Digest Dis	31	467-471	2013

Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, Korenaga K, Sakamoto A, Osaki Y, Aikata H, Chayama K, Suda T, Takano T, Miyoshi K, Koda M, Numata K, Tanaka H, Iijima H, Ochi H, Hirooka M, Imai Y, <u>Kudo M</u>	Hypovascular hepatic nodules showing hypointense on the hepatobiliary phase image of Gd-EOB-DTPA enhanced MRI to develop a hyper-vascular hepatocellular carcinoma: a nationwide retrospective study on their Natural course and Risk factors.	Digest Dis	31	472-479	2013
Minami Y, Hayaishi S, <u>Kudo M</u>	Radiofrequency ablation for hepatic malignancies: is the needle tract cauterization necessary for preventing iatrogenic bleeding?	Digest Dis	31	480-484	2013
Makino Y, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Horii M, <u>Kudo M</u> , Murakami T	Usefulness of the extracted-overlay function in CT/MR-ultrasonography fusion imaging for radiofrequency ablation of hepatocellular carcinoma.	Digest Dis	31	485-489	2013
<u>Kudo M</u> , Osaki Y, Matsunaga T, Kasugai H, Oka H, Seki T, the Osaka Liver Cancer Study Group	Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments.	Digest Dis	31	490-498	2013
<u>Kudo M</u>	Alpha-fetoprotein-L3: Useful or Useless for Hepatocellular Carcinoma?	Liver Cancer	2(3-4)	151-152	2013
Sakurai T, <u>Kudo M</u>	Molecular link between liver fibrosis and hepatocellular carcinoma.	Liver Cancer	2(3-4)	365-366	2013
Das K, <u>Kudo M</u> , Kitano M, Sakamoto H, Komaki T, Takagi T, Yamao K	Diagnostic value of endoscopic ultrasound-guided directional eFLOW in solid pancreatic lesions.	J Med Ultrason	40	211-218	2013
<u>Kudo M</u> , Shiina T, Moriyasu F, Iijima H, Tateishi R, Yada N, Fujimoto K, Morikawa H, Hirooka M, Sumino Y, Kumada T	JSUM ultrasound elastography practice guidelines: liver.	J Med Ultrason	40	325-357	2013
Kagawa Y, Okada M, Yagyu Y, Kumano S, Kanemitsu M, <u>Kudo M</u> , Murakami T	Optimal scan timing of hepatic arterial-phase imaging of hypervascular hepatocellular carcinoma determined by multiphase fast CT imaging technique.	Acta Radiol	54	843-850	2013

Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, Ichida T, <u>Kudo M</u> , Ku Y, Kokudo N, Sakamoto M, Nakashima O, Takayama T, Matsui O, Matsuyama Y, Yamamoto K, the Liver Cancer Study Group of Japan	Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan.	Brit J Cancer	109	1904-1907	2013
Cheng AL, Kang YK, Lin DY, Park JW, <u>Kudo M</u> , Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Lowenthal SP, Lanzalone S, Yang L, Lechuga MJ, Raymond E, for the SUN1170 HCC Study Group	Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.	J Clin Oncol	10; 31	4067-4075	2013
Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Avina JR, <u>Kudo M</u> , Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL	Brivanib versus Sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase 3 BRISK-FL study.	J Clin Oncol	1; 31	3517-3524	2013
Llovet JM, Decaens T, Raoul JL, Boucher E, <u>Kudo M</u> , Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc, JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW	Brivanib in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: or for whom sorafenib failed results from the randomized phase 3 BRISK-PS study.	J Clin Oncol	1; 31	3509-3516	2013
Lencioni R, <u>Kudo M</u> , Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ	GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.	Int J Clin Pract		1-9	2013
Nishida N, <u>Kudo M</u> , Nishimura T, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Yokomichi N, Nagasaka T, Goel A	Unique association between global DNA ypomethylation and hromosomal alterations in human hepatocellular carcinoma.	Plos One	8(9)	e72312	2013

Minami Y, Okumura N, Yamamoto N, Tsuji N, Kono Y, <u>Kudo M</u>	Quantification of tumor vascularity with contrast-enhanced ultrasound for early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of three cases.	J Med Ultrason	28	15-19	2012
Minami Y, Kitai S, <u>Kudo M</u>	Treatment response assessment of radiofrequency ablation for hepatocellular carcinoma: Usefulness of virtual CT sonography with magnetic navigation.	Eur J Radiol	81	e277-280	2012
Takayasu K, Arii S, <u>Kudo M</u> , Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M	Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.	J Hepatol	56	886-892	2012
<u>Kudo M</u> , Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, Izumi N, Matsui O	Current status of hepatocellular carcinoma treatment in Japan: Case study and discussion-voting system.	Clin Drug Invest	32	suppl. 2:37-51	2012
Saito J, Kim SR, <u>Kudo M</u> , Imoto S, Ando K, Nakajima T, Fukuda K, Otono Y, Kim SK, Komaki T, Yano H, Nakashima O, Sugimoto K, Matsuoka T	Well-differentiated hepatocellular carcinoma detected as hypovascularity by only CT during hepatic arteriography.	Intern Med	51	885-890	2012
Lencioni R, <u>Kudo M</u> , Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA	First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study.	Int J Clin Pract	66	675-683	2012
Okada M, Ishii K, Numata K, Hyodo T, Kumano S, Kitano M, <u>Kudo M</u> , Murakami T	Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function ?	Hepatob Pancreatic Dis Int	11	307-313	2012
Hagiwara S, <u>Kudo M</u> , Nagai T, Inoue T, Ueshima K, Nishida N, Watanabe T, Sakurai T	Activation of JNK and high expression level of CD133 predict a poor response to Sorafenib in hepatocellular carcinoma.	Brit J Cancer	106	1997-2003	2012



Shiina T, Maki T, Yamakawa M, Mitake T, <u>Kudo M</u> , Fujimoto K	Mechanical model analysis for quantitative evaluation of liver fibrosis based on ultrasound tissue elasticity imaging.	Jpn J Appl Phys	51	07GF11-1-8	2012
Takahashi K, Kashida H, <u>Kudo M</u>	Hepatic nodules associated with an inferior mesenteric arteriovenous malformation.	Internal Med	51	2753-2755	2012
<u>Kudo M</u>	Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail?	Liver Cancer	1(2)	59-60	2012
<u>Kudo M</u>	Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.	Liver Cancer	1(2)	62-70	2012
<u>Kudo M</u>	Viral Hepatitis and Hepatocellular carcinoma: Update in 2012.	Digest Dis	30	539-540	2012
Hagiwara S, Sakurai T, Nishina S, Tanaka K, Ikeda M, Ueshima K, Minami Y, Inoue T, Yada N, Kitai S, Takita M, Nagai T, Hayaishi S, Arizumi T, Park AM, Munakata H, Nishida N, <u>Kudo M</u>	Characteristic pattern of reactivation of hepatitis B virus during chemotherapy for solid cancers	Digest Dis	30	541-546	2012
Nishida N, Arizumi T, Hayaishi S, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Ikai I, <u>Kudo M</u>	Gender differences in the livers of patients with hepatocellular carcinoma and chronic hepatitis C infection.	Digest Dis	30	547-553	2012
Ueda T, Tsuchiya K, Hashimoto S, Inoue T, Inao M, Tanaka A, Kaito M, Imazaki F, Nishiguchi S, Mochida S, Yokosuka O, Yatsuhashi H, Izumi N, <u>Kudo M</u> , for RETRY study group	Retreatment with peginterferon alfa-2a plus ribavirin in patients who failed previous peginterferon alfa-2b plus ribavirin combination therapy.	Digest Dis	30	554-560	2012
Hagiwara S, Sakurai T, Takita M, Ueshima K, Minami Y, Inoue T, Yada N, Kitai S, Nagai T, Hayaishi S, Arizumi T, Nishida N, <u>Kudo M</u>	Risk of HCC development in cases of hepatitis C treated by long-term, low-dose PEG-IFN $\alpha$ 2a.	Digest Dis	30	561-567	2012

Kobayashi S, Kim SR, Imoto S, Ando K, Hirakawa M, Saito J, Fukuda K, Otono Y, Sakaki M, Tsuchida S, Kim SK, Hayashi Y, Nakano M, <u>Kudo M</u>	Histopathological diagnosis of early HCC through biopsy -efficacy of victoria blue and cytokeratin 7 staining-.	Digest Dis	30	574-579	2012
Tsuchida S, Fukumoto T, Toyokawa A, Awazu M, Kusunoki N, Kido M, Takahashi M, Tanaka M, Kuramitsu K, Kim SR, <u>Kudo M</u> , Ku Y	Novel non-trocar technique for laparoscopic radiofrequency ablation.	Digest Dis	30	588-591	2012
Minami Y, <u>Kudo M</u>	Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage.	Digest Dis	30	592-597	2012
<u>Kudo M</u> , Ueshima K, Arizumi T	Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a aingle center experience.	Digest Dis	30	609-616	2012
Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, Ishii K, Tanigawa N, Imai Y, <u>Kudo M</u> , Murakami T	Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging.	Eur J Radiol	81	1460-1464	2012
Nishida N, <u>Kudo M</u> , Nagasaka T, Ikai I, Goel A	Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma.	Hepatology	56	994-1003	2012
<u>Kudo M</u>	Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma.	World J Gastroenterol	18	6005-6017	2012
<u>Kudo M</u>	Japan's successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance.	Liver Cancer	1(3)	141-143	2012
Okusaka T, Kasugai H, Ishii H, <u>Kudo M</u> , Sata M, Tanaka K, Shioyama Y, Chayama K, Kumada H, Yoshikawa M, Seki T, Saito H, Hayashi N, Shiratori K, Okita K, Sakaida I, Honda M, Kusumoto Y, Tsutsumi T, Sakata K	A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma.	Invest New Drug	30	2015-2025	2012

Hagiwara S, <u>Kudo M</u> , Chung H, Ueshima K, Inoue T, Haji S, Watanabe T, Park AM, Munakata H, Sakurai T	Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma.	Hepatol Res	42	394-400	2012
Sakurai T, <u>Kudo M</u> , Umemura A, He G, Elsharkawy AM, Seki E, Karin M	p38 $\alpha$ inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species.	Cancer Res	73	215-224	2012
<u>Kudo M</u>	Targeted therapy for liver cancer: updated review in 2012.	Curr Cancer Drug Tar	12	1062-1072	2012
Kaneko S, Furuse J, <u>Kudo M</u> , Ikeda K, Honda M, Nakamoto Y, Onchi M, Shiota G, Yokosuka O, Sakaida I, Takehara T, Ueno Y, Hiroishi K, Nishiguchi S, Moriwaki H, Yamamoto K, Sata M, Obi S, Miyayama S, Imai Y	Guideline on the use of new anticancer drugs for the treatment of hepatocellular carcinoma 2010 update.	Hepatol Res	42	523-542	2012
Inoue T, <u>Kudo M</u> , Komuta M, Hayaishi S, Ueda T, Takita M, Kitai S, Hatanaka K, Yada N, Hagiwara S, Chung H, Sakurai T, Ueshima K, Sakamoto M, Maenishi O, Hyodo T, Okada M, Kumano S, Murakami T	Assessment of Gd-EOB-DTPA- enhanced MRI for HCC and Dysplastic nodule and comparison of detection sensitivity versus MDCT.	J Gastroenterol	47	1036-1047	2012
Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Matsumoto K, Saijo N, <u>Kudo M</u> , Nishio K	Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.	Mol Cancer Ther	10	169-177	2011
<u>Kudo M</u> , Hatanaka K, Kumada T, Toyoda H, Tada T	Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma.	Am J Gastroenterol	106	368-370	2011
Kudo K, Arao T, Tanaka K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, Velasco M, Fujita Y, Saijo N, <u>Kudo M</u> , Nishio K	Antitumor activity of BIBF 1120, a vascular endothelial growth factor-2 inhibitor and use of VEGR2+pTYR+leucocyte as a pharmacodynamic biomarker.	Clin Cancer Res	17	1373-1381	2011

Hagiwara S, <u>Kudo M</u> , Ueshima K, Chung H, Yamaguchi M, Takita M, Haji S, Kimura M, Arao T, Nishio K, Park AM, Munakata H	The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+pegylated interferon $\alpha$ -2b therapy against advanced hepatocellular carcinoma.	J Gastroenterol	46	212-221	2011
Kagawa Y, Okada M, Kumano S, Katsube T, Imaoka I, Tanigawa N, Ishii K, <u>Kudo M</u> , Murakami T	Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid-enhanced MR.	J Magn Reson Imaging	33	864-872	2011
Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokmi M, <u>Kudo M</u>	Management of hepatitis B: Consensus of Japan Society of Hepatology 2009.	Hepatol Res	41	1-21	2011
Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, <u>Kudo M</u> , Kitagaki H, Murakami T:	Estimation of liver function using T1 mapping onGd-EOB-DTPA-enhanced magnetic resonance imaging.	Invest Radiol	46	277-283	2011
Minami Y, <u>Kudo M</u>	Radiofrequency ablation of hepatocellular carcinoma: A literature review.	Int J Hepatol		104685 (Epub May page1-9)	2011
Eguchi S, Kanematsu T, Arii S, Omata M, <u>Kudo M</u> , Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M, for the Liver Cancer Study Group of Japan	Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma.	Brit J Surg	98	552-557	2011
<u>Kudo M</u>	Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.	Digest Dis	29	273-277	2011
<u>Kudo M</u>	Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.	Digest Dis	29	289-302	2011
<u>Kudo M</u>	mTOR inhibitor for the treatment of hepatocellular carcinoma.	Digest Dis	29	310-315	2011
<u>Kudo M</u>	Future treatment option for hepatocellular carcinoma: a focus on brivanib.	Digest Dis	29	316-320	2011

Ueshima K, <u>Kudo M</u> , Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H, Sakurai T	Des- $\gamma$ -carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of Sorafenib for hepatocellular carcinoma.	Digest Dis	29	321-325	2011
Hayaishi S, Chung H, <u>Kudo M</u> , Ishikawa E, Takita M, Ueda T, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ueshima K	Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis.	Digest Dis	29	326-332	2011
<u>Kudo M</u> , Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M	Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guideline proposed by the Japan Society of Hepatology (JSH) 2010 updated version.	Digest Dis	29	339-364	2011
Yoshida H, Shiratori Y, <u>Kudo M</u> , Shiina S, Mizuta T, Kojiro M, Yamamoto K, Koike Y, Saito K, Koyanagi N, Kawabe T, Kawazoe S, Kobashi H, Kasugai H, Osaki Y, Araki Y, Izumi N, Oka H, Tsuiji K, Toyota J, Seki T, Osawa T, Masaki N, Ichinose M, Seike M, Ishikawa A, Ueno Y, Tagawa K, Kuromatsu R, Sakisaka S, Ikeda H, Kuroda H, Hokuryu H, Yamashita T, Sakaida I, Katamoto T, Kikuchi K, Nomoto M, Omata M	Effect of vitamin K2 on the recurrence of hepatocellular carcinoma.	Hepatology	54	532-540	2011
Chung H, Watanabe T, <u>Kudo M</u> , Chiba T	Correlation between hyporesponsiveness to Toll-like receptor ligands and liver dysfunction in patients with chronic hepatitis C virus infection.	J Viral Hepat	18	e561-567	2011
<u>Kudo M</u> , Imanaka K, Chiba N, Nakachi K, Tak WT, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K	Phase III study of Sorafenib after transarterial chemoembolization in Japanese and Korean patients with unresectable hepatocellular carcinoma.	Eur J Cancer	47	2117-2127	2011

Llovet JM, Paradis V, <u>Kudo M</u> , Zucman-Rossi J	Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma.	Liver Transplant	17	S67-71	2011
<u>Kudo M</u>	Tailor-made therapy for viral hepatitis: Recent advances.	Digestion	84	1-4	2011
Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Nakajima T, Ando K, Fukuda K, Otono Y, Kim KI, Ohtani A, Sugimoto K, Hasegawa Y, Fujinami A, Ohta M, Hotta H, Maekawa Y, Hayashi Y, <u>Kudo M</u>	Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.	Digestion	84	5-9	2011
Kim SR, Saito J, Imoto S, Komaki T, Nagata Y, Kim KI, Sasase N, Kimura N, Sasatani K, Konishi E, Hasaegawa Y, Fujinami A, Ohta M, Ei-Shamy A, Tanaka Y, Sugano M, Sakashita M, Nakamura A, Tsuchida S, Makino T, Kawada T, Nakajima T, Morikawa T, Muramatsu A, Kasugai H, Hotta H, <u>Kudo M</u>	Double-filtration plasmapheresis plus interferon- $\beta$ for HCV-1b patients with non-sustained virological response to previous combination therapy.	Digestion	84	10-16	2011
Kim SK, Marusawa H, Eso Y, Nishikawa H, Ueda Y, Kita R, Kimura T, Chiba T, Osaki Y, <u>Kudo M</u>	Clinical characteristics of non-B non-C hepatocellular carcinoma: A single-center retrospective study.	Digestion	84	43-49	2011
Takita M, Hagiwara S, Arizumi T, Hayaishi S, Ueda T, Kitai S, Yada N, Inoue T, Minami Y, Chung H, Ueshima K, Sakurai T, <u>Kudo M</u>	Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.	Digestion	84	56-61	2011
<u>Kudo M</u>	Hepatocellular carcinoma in 2011 and beyond: From the pathogenesis to molecular targeted therapy.	Oncology	81	1-10	2011
Sakurai T, <u>Kudo M</u>	Signaling pathways governing tumor angiogenesis.	Oncology	81	24-29	2011
Sakurai T, <u>Kudo M</u> , Itoh K, Ryu U, Higashitsuji H, Fujita J	Adriamycin enhances proteasome-mediated generation of the proapoptotic processed form of MAGE-A4 in hepatoma cells.	Oncology	81	30-35	2011

<u>Kudo M</u>	Adjuvant therapy after curative treatment for hepatocellular carcinoma.	Oncology	81	50-55	2011
Alaboudy A, Inoue T, Hatanak K, Chung H, Hyodo T, Kumano S, Murakami T, Moustafa EFA, <u>Kudo M</u>	Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography.	Oncology	81	66-72	2011
<u>Kudo M</u>	Diagnostic imaging of hepatocellular carcinoma: Recent progress.	Oncology	81	73-85	2011
Inuzuka T, Nishikawa H, Sekikawa A, Takeda H, Henmi S, Sakamoto A, Saito S, Kitamura R, Kimura T, Osaki Y, <u>Kudo M</u>	Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with Sorafenib: A case report.	Oncology	81	152-157	2011
Han KH, <u>Kudo M</u> , Ye SL, Choi JY, Poon RTP, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL	Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.	Oncology	81	158-164	2011
Kim SR, Yang J, <u>Kudo M</u> , Hino O	Recent advances in the management of chronic hepatitis B.	Hepat Mon	11	601-611	2011
Minami Y, <u>Kudo M</u>	Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma.	World J Gastroenterol	17	4952-4959	2011
Higashi T, Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, <u>Kudo M</u> , Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, Sobue T for the Liver Cancer Study Group of Japan	Demonstration of quality of care measurement using the Japanese liver cancer registry.	Hepatol Res	41	1208-1215	2011
Suzuki H, Murata K, Gotoh T, Kusano M, Okano H, Oyamada T, Yasuda Y, Imamura M, <u>Kudo M</u> , Mizokami M, Sakamoto A	Phenotype-dependent production of des- $\gamma$ -carboxy prothrombin in hepatocellular carcinoma.	J Gastroenterol	46	1219-1229	2011

Bridges JF, Joy SM, Gallego G, <u>Kudo M</u> , Ye SL, Han KH, Cheng AL, Blauvelt BM	Needs for hepatocellular carcinoma control policy in the Asia-pacific region.	Asian Pac J Cancer Prev	12	2585-2591	2011
Bridges JF, Gallego G, <u>Kudo M</u> , Okita K, Han KH, Ye SL, Blauvelt BM	Identifying and prioritizing strategies for comprehensive liver cancer control in Asia.	BMC Health Serv Res	11	298 (12p)	2011
<u>T. Shiina</u>	JSUM ultrasound elastography practice guidelines: basics and terminology	J. of Medical Ultrasonics	40 (4)	309-323	2013
M.Kudo, <u>T.Shiina</u> , F. Moriyasu, H. Iijima, R. Tateishi, N. Yada, K. Fujimoto, H. Morikawa, M. Hirooka, Y. Sumino	JSUM ultrasound elastography practice guidelines: liver, J. of Medical Ultrasonics	J. of Medical Ultrasonics	40 (4)	325-357	2013
T. Shiina, T.Maki, M.Yamakawa, T.Mitake, M.Kudo, K.Fujimoto,	Mechanical Model Analysis for Quantitative Evaluation of Liver Fibrosis Based on Ultrasound Tissue Elasticity Imaging	Jpn. Japanese Journal of Applied Physics	51	07GF11-1~8.	2012
Kengo Kondo, Makoto Yamakawa, and <u>Tsuyoshi Shiina</u> ,	Experimental Validation of Displacement Vector Measurement Based on Two-Dimensional Modulation Method with Virtual Hyperbolic Scanning,”	Jpn. Japanese Journal of Applied Physics.	51	07GF10-1~6,	2012
Makoto Yamakawa, <u>Tsuyoshi Shiina</u>	Makoto Yamakawa, <u>Tsuyoshi Shiina</u>	Jpn. Japanese Journal of Applied Physics	51	.07GF12-1~12	2012
<u>T. Shiina</u> , M. Yamakawa, M. Kudo, A. Tonomura, T. Mitake,	Mechanical Model Analysis for Quantitative Evaluation of Liver Fibrosis based on Real-Time Tissue Elastography,”	Proc. the 10 <sup>th</sup> International Tissue Elasticity Conference ,			2012
<u>Fujimoto K</u> , Kato M, Kudo M, et al.	Novel Image Analysis Method using Ultrasound Elastography for Non-invasive Evaluation of Hepatic Fibrosis in Patients with Chronic Hepatitis C.	Oncology	84(supple 1)	3-12	2013
Kudo M, Shiina T, Moriyasu F, Iijima H, Tateishi R, Yada N, <u>Fujimoto K</u> , Morikawa H, Hirooka M, Sumino Y, Kumada T.	JSUM Ultrasound Elastography Practice Guideline: Liver	Journal of Medical Ultrasonics	40	325-357	2013



Nishikawa H, <u>Osaki Y.</u>	Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma.	Hepatology Research	44	149-158	2013
Nishikawa H, <u>Osaki Y.</u> , Iguchi E, Koshikawa Y, Aoko S, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Ishikawa T, Saito S, Nasu A, Kita R, Kimura T.	The effect of long-term supplementation with branched-chain amino acid granules in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation.	Journal of Clinical Gastroenterology	47	359-366	2013
<u>Osaki Y.</u> , Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, Nishikawa H, Saito S, Henmi S, Sakamoto A, Esoda Y, Chiba T.	Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study.	Journal of Gastroenterology	47	444-451	2012
Nasu A, Marusawa H, Ueda Y, Nishijima N, Takahashi K, <u>Osaki Y.</u> , Yamashita Y, Inokuma T, Tamada T, Fujiwara T, Sato F, Shimizu K, Chiba T.	Genetic Heterogeneity of Hepatitis C Virus in Association with Antiviral Therapy Determined by Ultra-Deep Sequencing.	PLoS ONE	6	e24907	2011
Soo Ki Kim, Hiroyuki Marusawa, Yuji Eso, Hiroki Nishikawa, Yoshihide Ueda, Ryuichi Kita, Toru Kimura, Tsutomu Chiba, <u>Yukio Osaki.</u> , Masatoshi Kudo	Clinical Characteristics of Non-B Non-C Hepatocellular Carcinoma: A Single-Center Retrospective Study.	Digestion	84	43-49	2011
Noritaka Wakui	Arrival time parametric imaging using Sonazoid-enhanced ultrasonography is useful for the detection of spoke-wheel patterns of focal nodular hyperplasia smaller than 3 cm.	Experimental and Therapeutic Medicine	5	1551-1554	2013
Hidenari Nagai	Influence of etiology on host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy	Hepato-Gastroenterology	60	858-862	2013

Takanori Mukouzu	Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.	Anticancer Research	33	1013-1022	2013
Kazue Shiozawa	Usefulness of contrast-enhanced ultrasonography in the diagnosis of ruptured hepatocellular carcinoma.	Clin J Gastroenterol	6	334-337	2013
Noritaka Wakui, et al.	Usefulness of arrival time parametric imaging in evaluating the degree of liver disease progression in chronic hepatitis C infection.	J Ultrasound Med	31	378-382	2012
Noritaka Wakui, et al.	A case of poorly differentiated hepatocellular carcinoma with intriguing ultrasonography findings.	Oncology letters	4	393-397	2012
Kazue Shiozawa, et al.	Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography	W J of Gastroenterology	18	5753-5758	2012
Noritaka Wakui, et al.	Drinking status of heavy drinkers detected by arrival time parametric imaging using Sonazoid-enhanced ultrasonography: study of two cases.	Case Rep Gastroenterol	5	100-109	2011
Noritaka Wakui, et al.	Diagnosis of hepatic hemangioma by parametric imaging using Sonazoid-enhanced US.	Hepato-Gastroenterology	58	1431-1435	2011
Nojiri S, Kusakabe A, Fujiwara K, Shinkai N, Matsuura K, Iio E, Miyaki T, Joh T	Noninvasive evaluation of hepatic fibrosis in HCV-infected patients using EOB-MR imaging	Journal of Gastroenterology and Hepatology	Jun;28(6)	1032-9	2013
Nojiri S, Fujiwara K, Shinkai N, Endo M and Joh T	A case of rapidly developed splenomegaly after percutaneous transhepatic obliteration (PTO)	J liver	2	3	2013
Kusakabe A, Nojiri S, Shinkai N, Matsuura K, Iio E, Miyaki T, Joh T	Case-control study of the therapeutic effect of newly developed 4D US and conventional 2D US	Journal of Medical Ultrasonics	40	39-46	2013

Nojiri S, Kusakabe A, Shinkai N, Matsuura K, Iio E, Miyaki T, Nomura T, Sobue S, Sano H, Hasegawa I, Ohno T, Takahashi Y, Orito E, and Joh T	Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma	Cancer Management and Research	4	423-429	2012
Nojiri S, Kusakabe A, Shinkai N, Matsuura K, Iio E, Miyaki T, Joh T	Factors influencing distant recurrence of hepatocellular carcinoma following combined radiofrequency ablation and transarterial chemoembolization therapy in patients with hepatitis C	Cancer Management and Research	3	267- 272	2011
Sato S, Tobita H, Miyake T, Saitou T, Kinoshita T.	Bleeding in abdominal cavity revealed by contrast-enhanced Ultrasonography	Journal of Medical Ultrasonics	40	289-91	2013
Hanaoka T, Sato S, Tobita H, Miyake T, Ishihara S, Akagi S, Amano Y, Kinoshita Y	Clinical significance of the highly sensitive fucosylated fraction of $\alpha$ -fetoprotein in patients with chronic liver disease.	Journal of Gastroenterology and Hepatology	26	739-744	2011
Uesugi K, Hiasa Y, Tokumoto Y, Mashiba T, Koizumi Y, Hirooka M, Abe M, Matsuura B, Onji M	Wilms' tumor 1 gene modulates Fas-related death signals and anti-apoptotic functions in hepatocellular carcinoma. .	Journal of Gastroenterology	48(9)	1069-1080	2013
Hiraoka A, Hirooka M, Ochi H, Koizumi Y, Shimizu Y, Shiraishi A, Yamago H, Tanihira T, Miyata H, Ninomiya T, Kawasaki H, Ishihara Y, Sogabe I, Inoue T, Abe M, Hiasa Y, Matsuura B, Onji M, Michitaka K	Importance of screening for synchronous malignant neoplasms in patients with hepatocellular carcinoma : impact of FDG PET/CT.	Liver International	33(7)	1085-1091	2013
Takeji S, Hirooka M, Koizumi Y, Tokumoto Y, Abe M, Ikeda Y, Nadano S, Hiasa Y, Onji M	Des-gamma-carboxy prothrombin identified by P-11 and P-6 antibodies reflects prognosis for patients with hepatocellular carcinoma.	Journal of Gastroenterology and Hepatology	28(4)	671-677	2013
Watanabe T, Hiasa Y, Tokumoto Y, Hirooka M, Abe M, Ikeda Y, Matsuura B, Chung RT, Onji M	Protein kinase R modulates c-Fos and c-Jun signaling to promote proliferation of hepatocellular carcinoma with hepatitis C virus infection.	PLoS One	8(7)	e67750	2013

Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, <u>Hiasa Y</u> , Toyoki Y, Hakamada K, Yasui K, Kumada T, Toyoda H, Sato S, Hiasa H, Kuzuya T, Tsuchiya K, Izumi N, Arii S, Nishio K, Kudo M	FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.	Hepatology	57(4)	1407-1415	2013
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo M, Takaguchi K, <u>Hiasa Y</u> , Chayama K, Yatsushashi H, Oketani M, Kumada H.	Inhibition of hepatocellular carcinoma by PegIFN $\alpha$ -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.	Journal of Gastroenterology	48(3)	382-392	2013
Miyake T, Kumagi T, Hirooka M, Furukawa S, Koizumi M, Tokumoto Y, Ueda T, Yamamoto S, Abe M, Kitai K, <u>Hiasa Y</u> , Matsuura B, Onji M.	Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study.	Journal of Gastroenterology	48(3)	413-422	2013
Tada F, Abe M, Hirooka M, Ikeda Y, <u>Hiasa Y</u> , Lee Y, Jung NC, Lee WB, Lee HS, Bae YS, Onji M.	Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.	International Journal of Oncology	41	1601-9	2012
Yamamoto Y, <u>Hiasa Y</u> , Murakami H, Ikeda Y, Yamanishi H, Abe M, Matsuura B, Onji M.	Rapid alternative absorption of dietary long-chain fatty acids with upregulation of intestinal glycosylated CD36 in liver cirrhosis.	American Journal of Clinical Nutrition	96	90-101	2012
Ochi H, Hirooka M, Koizumi Y, Miyake T, Tokumoto Y, Soga Y, Tada F, Abe M, <u>Hiasa Y</u> , Onji M.	Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases.	Hepatology	56	1271-8	2012
Hirooka M, Ochi H, Koizumi Y, Kisaka Y, Abe M, Ikeda Y, Matsuura B, <u>Hiasa Y</u> , Onji M.	Splenic Elasticity Measured with Real-time Tissue Elastography Is a Marker of Portal Hypertension.	Radiology	261(3)	960-968	2011